OncoMatch/Clinical Trials/NCT06430112
Liposomal Bupivacaine vs Ropivacaine for TAPBs
Is NCT06430112 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Liposomal Bupivacaine and Ropivacaine for abdominal tumor.
Treatment: Liposomal Bupivacaine · Ropivacaine — Few studies have compared the efficacy of ultrasound (US)-guided TAP blocks with Liposomal bupivacaine(LB) versus ropivacaine in reducing postoperative opioid usage in patients undergoing laparoscopic lower abdominal tumor Resection. Therefore, we are conducting this prospective, randomized controlled trial to compare the postoperative analgesic effects of LB and ropivacaine for TAP blocks among patients undergoing laparoscopic colorectal procedures.
Check if I qualifyExtracted eligibility criteria
Performance status
ASA 2–3
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify